Moderna and Merck Cancer Vaccine Shows Promise in Melanoma Trial
· Business · CNBC, MarketWatch, Reuters
A personalized mRNA-based cancer vaccine developed by Moderna and Merck has demonstrated positive results in a phase three trial involving over 1,100 patients with advanced melanoma. When used alongside Merck's immunotherapy drug Keytruda, the vaccine significantly extended the time patients lived without their cancer returning. The treatment also reduced the risk of the cancer spreading to distant parts of the body compared to using Keytruda alone. The companies plan to present these findings at an upcoming international medical meeting, though a timeline for regulatory approval in the US remains unconfirmed. This trial marks the first late-stage study for the experimental regimen, which aims to provide a new option for a form of skin cancer that causes a majority of melanoma-related deaths.
Why it matters
This development offers a potential breakthrough for high-risk melanoma patients, providing a more effective, personalized alternative to current standard-of-care treatments.
Read the original report — CNBC
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.